Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Iptacopan in IgA Nephropathy
NCT03373461Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 2 trial of Iptacopan in IgA nephropathy (IgAN), sponsored by Novartis. Started Feb 2018; status: completed.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT03373461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03373461.